These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18204765)

  • 21. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients.
    Fleischhack G; Schmidt-Niemann M; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    Support Care Cancer; 2001 Jul; 9(5):372-9. PubMed ID: 11497392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restricted use of glycopeptides in paediatric cancer patients with fever and neutropenia.
    Simon A; Gröger N; Wilkesmann A; Hasan C; Wiszniewsky G; Engelhart S; Kramer MH; Bode U; Ammann RA; Fleischhack G
    Int J Antimicrob Agents; 2006 Nov; 28(5):417-22. PubMed ID: 17046210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial.
    Gómez L; Estrada C; Gómez I; Márquez M; Estany C; Martí JM; Bastús R; Cirera L; Quintana S; Garau J
    Eur J Clin Microbiol Infect Dis; 2010 Apr; 29(4):417-27. PubMed ID: 20195673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
    Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
    Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
    Böhme A; Shah PM; Stille W; Hoelzer D
    Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
    Hazel DL; Graham J; Dickinson JP; Newland AC; Kelsey SM
    J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
    Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
    Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
    Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
    Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia.
    Del Favero A; Menichetti F; Martino P; Bucaneve G; Micozzi A; Gentile G; Furno P; Russo D; D'Antonio D; Ricci P; Martino B; Mandelli F;
    Clin Infect Dis; 2001 Oct; 33(8):1295-301. PubMed ID: 11565068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
    Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
    J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cefepime versus piperacillin/tazobactam with or without amikacin in the treatment of febrile hematological and oncological neutropenic patients in an internal medicine ward].
    Shichmanter R; Miller EB; Shtalrid M; Landau Z
    Harefuah; 2010 Dec; 149(12):765-8, 813, 812. PubMed ID: 21916097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis.
    Martino P; Micozzi A; Gentile G; Raccah R; Girmenia C; Mandelli F
    Clin Infect Dis; 1992 Aug; 15(2):290-4. PubMed ID: 1387806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study.
    Uygun V; Karasu GT; Ogunc D; Yesilipek A; Hazar V
    Pediatr Blood Cancer; 2009 Oct; 53(4):610-4. PubMed ID: 19484759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
    Ichikawa M; Suzuki D; Ohshima J; Cho Y; Kaneda M; Iguchi A; Ariga T
    Pediatr Blood Cancer; 2011 Dec; 57(7):1159-62. PubMed ID: 21438131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.